Jun Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jun Guo has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Chanjuan Hao
Beijing Key Laboratory for Genetics of Birth Defects, Beijing Pediatric Research Institute, MOE Key Laboratory of Major Diseases in Children, Capital Medical University, Center of Rare Diseases, National Center for Children's Health, Beijing Children's Hospital, Beijing, China; Henan Key Laboratory of Pediatric Inherited & Metabolic Diseases, Henan Children's Hospital, Zhengzhou Hospital of Beijing Children's Hospital, Zhengzhou, China
4 shared publications- Wei Li
Beijing Key Laboratory for Genetics of Birth Defects, Beijing Pediatric Research Institute, MOE Key Laboratory of Major Diseases in Children, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
4 shared publications Wei Li
3 shared publications- Huimin Li
Department of Genetics and Reproductive Medicine, Shunyi Maternal and Children’s Hospital of Beijing Children’s Hospital, Beijing 101300, China
2 shared publications Ruolan Guo
Beijing Key Laboratory for Genetics of Birth Defects, Beijing Pediatric Research Institute, MOE Key Laboratory of Major Diseases in Children, Genetics and Birth Defects Control Center, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China
2 shared publicationsXuyun Hu
Beijing Key Laboratory for Genetics of Birth Defects, Beijing Pediatric Research Institute, MOE Key Laboratory of Major Diseases in Children, Genetics and Birth Defects Control Center, Beijing Children's Hospital, National Center for Children's Health Capital Medical University Beijing China
2 shared publications
Latest Publications
- Open Access
- 28 May 2025
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 45 (05) , 343-360
Single-cell RNAseq of Angiotensin II-induced abdominal aortic tissue identifies aneurysm-associated cell clusters in C57BL/6J mice
Abdominal aortic aneurysms (AAAs) are life-threatening due to the rupture of aorta. Different vascular cell types are known to be involved in AAA development. However, whether any specific cell cluster plays a critical role during AAA formation is unknown. Angiotensin II (Ang II) infused mouse AAA models are commonly used to study the development and progression of AAA. We here investigate the incidence of AAA at different ages or different doses of Ang II in C57BL/6J mice. There was no AAA formation at a concentration of 1.44 mg/kg/day or 2.16 mg/kg/day at the age of 14 weeks. At the age of 20 weeks and 32 weeks, the incidence of AAA was 18.2% (6/21) and 57.1% (4/7), respectively, with a concentration of 1.44 mg/kg/day. Using single-cell RNA sequencing, we found that increased clusters of monocytes and neutrophils, macrophages, T cells, and B cells were the typical changes in AAA. A special cluster transformed from endothelial cells (malignant ECs) was identified, in which genesinvolved in lipid metabolism, including Cd36, Lpl, Gpihbp1, Fabp4, and Pparg, were highly expressed. Mice receiving Ang II treatment without AAA development showed increased fibroblasts, which may prevent the occurrence of AAA. Through cell–cell interaction analysis, we found that the Cxcl12–Cxcr4/Ackr3 axis, which functions in inflammatory ligand– receptor binding, may play a role in AAA formation. Our results reveal that specific cell clusters may contribute to the progression or prevention of AAA formation. These findings provide new clues for the pathogenesis and intervention of AAA.
- 28 May 2025
- Published by Portland Press Ltd. in Bioscience Reports
- Vol. 45 (05) , 343-360
Open AccessSingle-cell RNAseq of Angiotensin II-induced abdominal aortic tissue identifies aneurysm-associated cell clusters in C57BL/6J mice
Abdominal aortic aneurysms (AAAs) are life-threatening due to the rupture of aorta. Different vascular cell types are known to be involved in AAA development. However, whether any specific cell cluster plays a critical role during AAA formation is unknown. Angiotensin II (Ang II) infused mouse AAA models are commonly used to study the development and progression of AAA. We here investigate the incidence of AAA at different ages or different doses of Ang II in C57BL/6J mice. There was no AAA formation at a concentration of 1.44 mg/kg/day or 2.16 mg/kg/day at the age of 14 weeks. At the age of 20 weeks and 32 weeks, the incidence of AAA was 18.2% (6/21) and 57.1% (4/7), respectively, with a concentration of 1.44 mg/kg/day. Using single-cell RNA sequencing, we found that increased clusters of monocytes and neutrophils, macrophages, T cells, and B cells were the typical changes in AAA. A special cluster transformed from endothelial cells (malignant ECs) was identified, in which genesinvolved in lipid metabolism, including Cd36, Lpl, Gpihbp1, Fabp4, and Pparg, were highly expressed. Mice receiving Ang II treatment without AAA development showed increased fibroblasts, which may prevent the occurrence of AAA. Through cell–cell interaction analysis, we found that the Cxcl12–Cxcr4/Ackr3 axis, which functions in inflammatory ligand– receptor binding, may play a role in AAA formation. Our results reveal that specific cell clusters may contribute to the progression or prevention of AAA formation. These findings provide new clues for the pathogenesis and intervention of AAA.
- 10 October 2023
- Vol. 40 (10) , 1211-1216
[Clinical and genetic analysis of eight children with Primary hypertrophic cardiomyopathy].
To explore the clinical and genetic characteristics of eight children with Primary hypertrophic cardiomyopathy (HCM). Eight children with HCM admitted to the Department of Cardiology of Henan Children's Hospital from January 2018 to December 2021 were selected as the study subjects. Clinical data of the children were collected. Whole exome sequencing was carried out on two children, and trio whole exome sequencing was carried out on the remainder 6 children. Sanger sequencing was used to verify the candidate variants in the children and their parents, and the pathogenicity of the variants was evaluated based on the guidelines from the American College of Medical Genetics and Genomics (ACMG). The patients had included 5 males and 3 females, with their ages ranging from 5 to 13 years old. The average age of diagnosis was (7.87 ± 4.8) years old, and the cardiac phenotype showed non-obstructive HCM in all of the patients. WES has identified variants of the MYH7 gene in 4 children, including c.2155C>T (p.Arg719Trp), c.1208G>A (p.Arg403Gln), c.1358G>A (p.Arg453His), and c.1498G>A (p.Glu500Lys). Based on the guidelines from the ACMG, the first 3 variants were classified as pathogenic, while c.1498G>A (p.Glu500Lys) was classified as likely pathogenic (PM1+PM2_Supporting+PM6+PP3), which was also unreported previously. The remaining four children had all harbored maternal variants, including MYL2: c.173G>A (p.Arg58Gln; classified as pathogenic), TPM1: c.574G>A (p.Glu192Lys) and ACTC1: c.301G>A (p.Glu101Lys)(both were classified as likely pathogenic), and MYBPC3: c.146T>G (p.Ile49Ser; classified as variant of uncertain significance). Seven children were treated with 0.5 ~ 3 mg/(kg·d) propranolol, and their symptoms had improved significantly. They were followed up until September 30, 2022 without further cardiac event. Genetic testing can clarify the molecular basis for unexplained cardiomyopathy and provide a basis for clinical diagnosis and genetic counseling. Discovery of the c.1498G>A (p.Glu500Lys) variant has also expanded the spectrum of MYH7 gene mutations underlying HCM.
- 10 October 2023
- Vol. 40 (10) , 1211-1216
[Clinical and genetic analysis of eight children with Primary hypertrophic cardiomyopathy].
To explore the clinical and genetic characteristics of eight children with Primary hypertrophic cardiomyopathy (HCM). Eight children with HCM admitted to the Department of Cardiology of Henan Children's Hospital from January 2018 to December 2021 were selected as the study subjects. Clinical data of the children were collected. Whole exome sequencing was carried out on two children, and trio whole exome sequencing was carried out on the remainder 6 children. Sanger sequencing was used to verify the candidate variants in the children and their parents, and the pathogenicity of the variants was evaluated based on the guidelines from the American College of Medical Genetics and Genomics (ACMG). The patients had included 5 males and 3 females, with their ages ranging from 5 to 13 years old. The average age of diagnosis was (7.87 ± 4.8) years old, and the cardiac phenotype showed non-obstructive HCM in all of the patients. WES has identified variants of the MYH7 gene in 4 children, including c.2155C>T (p.Arg719Trp), c.1208G>A (p.Arg403Gln), c.1358G>A (p.Arg453His), and c.1498G>A (p.Glu500Lys). Based on the guidelines from the ACMG, the first 3 variants were classified as pathogenic, while c.1498G>A (p.Glu500Lys) was classified as likely pathogenic (PM1+PM2_Supporting+PM6+PP3), which was also unreported previously. The remaining four children had all harbored maternal variants, including MYL2: c.173G>A (p.Arg58Gln; classified as pathogenic), TPM1: c.574G>A (p.Glu192Lys) and ACTC1: c.301G>A (p.Glu101Lys)(both were classified as likely pathogenic), and MYBPC3: c.146T>G (p.Ile49Ser; classified as variant of uncertain significance). Seven children were treated with 0.5 ~ 3 mg/(kg·d) propranolol, and their symptoms had improved significantly. They were followed up until September 30, 2022 without further cardiac event. Genetic testing can clarify the molecular basis for unexplained cardiomyopathy and provide a basis for clinical diagnosis and genetic counseling. Discovery of the c.1498G>A (p.Glu500Lys) variant has also expanded the spectrum of MYH7 gene mutations underlying HCM.
- 3 May 2021
- Published by Wiley in Human Mutation
- Vol. 42 (7) , 891-900
Exome sequencing as the first‐tier test for pediatric respiratory diseases: A single‐center study
The high clinical and genetic heterogeneity makes it difficult to reach a confirmative diagnosis of suspected pediatric respiratory inherited diseases. Many patients with monogenic respiratory disorders could be missed without genetic testing. We performed a single‐center study in Beijing Children's Hospital to demonstrate the clinical utility of exome sequencing (ES) as a first‐tier test by evaluating the diagnostic yields of ES for inherited diseases with respiratory symptoms. A total of 107 patients were recruited in this study. We identified 51 pathogenic or likely pathogenic variants in 37 patients by ES (with or without copy number variants sequencing). The overall diagnostic yield was 34.6% (37/107). The most frequent disorders in our cohort were primary immunodeficiency disease (PIDs) (18/37, 48.6%) and primary ciliary dyskinesia (PCD) (9/37, 24.3%). We further reviewed the directive outcomes of genetic testing on the 37 positive cases. Our study demonstrated the effectiveness of ES as a first‐tier test in China for diagnosing monogenic diseases of the respiratory system. In the era of precision medicine, ES as a first‐tier test can rapidly make a molecular diagnosis and direct the intervention of the positive cases in pediatric respiratory medicine.
- 3 May 2021
- Published by Wiley in Human Mutation
- Vol. 42 (7) , 891-900
Exome sequencing as the first‐tier test for pediatric respiratory diseases: A single‐center study
The high clinical and genetic heterogeneity makes it difficult to reach a confirmative diagnosis of suspected pediatric respiratory inherited diseases. Many patients with monogenic respiratory disorders could be missed without genetic testing. We performed a single‐center study in Beijing Children's Hospital to demonstrate the clinical utility of exome sequencing (ES) as a first‐tier test by evaluating the diagnostic yields of ES for inherited diseases with respiratory symptoms. A total of 107 patients were recruited in this study. We identified 51 pathogenic or likely pathogenic variants in 37 patients by ES (with or without copy number variants sequencing). The overall diagnostic yield was 34.6% (37/107). The most frequent disorders in our cohort were primary immunodeficiency disease (PIDs) (18/37, 48.6%) and primary ciliary dyskinesia (PCD) (9/37, 24.3%). We further reviewed the directive outcomes of genetic testing on the 37 positive cases. Our study demonstrated the effectiveness of ES as a first‐tier test in China for diagnosing monogenic diseases of the respiratory system. In the era of precision medicine, ES as a first‐tier test can rapidly make a molecular diagnosis and direct the intervention of the positive cases in pediatric respiratory medicine.
- Open Access
LOXL4 Abrogation Does Not Exaggerate Angiotensin II-Induced Thoracic or Abdominal Aortic Aneurysm in Mice
It has been shown that thoracic aortic aneurysm and dissection (TAAD) could be a Mendelian trait caused by a single gene mutation. The LOX gene mutation leads to the development of human TAAD. The LOXL4 gene is a member of the lysyl oxidase gene family. We identified seven variants in the LOXL4 gene in 219 unrelated patients with TAAD by whole-exome sequencing (WES). To further investigate whether LOXL4 is a candidate causative gene for human TAAD, a LOXL4 knockout mouse was generated, and the mutant mice were treated by subcutaneous infusion of angiotensin II. We found that abrogation of LOXL4 did not induce a more severe thoracic or abdominal aortic aneurysm compared with the wild-type C57BL/6J mice. Our results suggest that LOXL4 may not play a major role in the development of angiotensin II-induced aortic aneurysm. The functional study using this animal model system is important for the evaluation of candidate genes of TAAD identified by WES.
Open AccessLOXL4 Abrogation Does Not Exaggerate Angiotensin II-Induced Thoracic or Abdominal Aortic Aneurysm in Mice
It has been shown that thoracic aortic aneurysm and dissection (TAAD) could be a Mendelian trait caused by a single gene mutation. The LOX gene mutation leads to the development of human TAAD. The LOXL4 gene is a member of the lysyl oxidase gene family. We identified seven variants in the LOXL4 gene in 219 unrelated patients with TAAD by whole-exome sequencing (WES). To further investigate whether LOXL4 is a candidate causative gene for human TAAD, a LOXL4 knockout mouse was generated, and the mutant mice were treated by subcutaneous infusion of angiotensin II. We found that abrogation of LOXL4 did not induce a more severe thoracic or abdominal aortic aneurysm compared with the wild-type C57BL/6J mice. Our results suggest that LOXL4 may not play a major role in the development of angiotensin II-induced aortic aneurysm. The functional study using this animal model system is important for the evaluation of candidate genes of TAAD identified by WES.
- 1 July 2020
- Published by Elsevier in Clinica Chimica Acta
- Vol. 506, 160-165
Identification of clinically relevant variants by whole exome sequencing in Chinese patients with sporadic non-syndromic type A aortic dissection
- 1 July 2020
- Published by Elsevier in Clinica Chimica Acta
- Vol. 506, 160-165
Identification of clinically relevant variants by whole exome sequencing in Chinese patients with sporadic non-syndromic type A aortic dissection
- Open Access
- 3 July 2019
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 7 (8) , e828
A novel de novo CASZ1 heterozygous frameshift variant causes dilated cardiomyopathy and left ventricular noncompaction cardiomyopathy
Background: Dilated cardiomyopathy (DCM) is the most common cardiomyopathy with a common presentation of heart failure. It has been reported that CASZ1 loss‐of‐function mutation contributes to familial DCM and congenital ventricular septal defect (VSD). To date, only two pathogenic variants in CASZ1 have been previously reported worldwide.Methods: To identify the causative variant in an 11‐month‐old Chinese boy with DCM and left ventricular noncompaction cardiomyopathy (LVNC), trio‐whole‐exome sequencing was performed followed by mutational analysis and Sanger sequencing.Results: An unreported de novo heterozygous frameshift variant (c.2443_2459delGTGGGCACCCCCAGCCT, p.Val815Profs*14) in CASZ1 was idenitified in the proband. The frameshift mutation in CASZ1 not only led to DCM but also presented an LVNC phenotype.Conclusion: We have identified a novel CASZ1 variant in a patient with combined DCM and LVNC for the first time, thus broadening the phenotypic spectrum of CASZ1 variants. Furthermore, this study emphasized the usefulness of whole‐exome sequencing for genetic diagnosis of cardiomyopathy.
- 3 July 2019
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 7 (8) , e828
Open AccessA novel de novo CASZ1 heterozygous frameshift variant causes dilated cardiomyopathy and left ventricular noncompaction cardiomyopathy
Background: Dilated cardiomyopathy (DCM) is the most common cardiomyopathy with a common presentation of heart failure. It has been reported that CASZ1 loss‐of‐function mutation contributes to familial DCM and congenital ventricular septal defect (VSD). To date, only two pathogenic variants in CASZ1 have been previously reported worldwide.Methods: To identify the causative variant in an 11‐month‐old Chinese boy with DCM and left ventricular noncompaction cardiomyopathy (LVNC), trio‐whole‐exome sequencing was performed followed by mutational analysis and Sanger sequencing.Results: An unreported de novo heterozygous frameshift variant (c.2443_2459delGTGGGCACCCCCAGCCT, p.Val815Profs*14) in CASZ1 was idenitified in the proband. The frameshift mutation in CASZ1 not only led to DCM but also presented an LVNC phenotype.Conclusion: We have identified a novel CASZ1 variant in a patient with combined DCM and LVNC for the first time, thus broadening the phenotypic spectrum of CASZ1 variants. Furthermore, this study emphasized the usefulness of whole‐exome sequencing for genetic diagnosis of cardiomyopathy.
- Open Access
- 14 August 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 13115
Wide mutation spectrum and frequent variant Ala27Thr of FBN1 identified in a large cohort of Chinese patients with sporadic TAAD
Genetic etiology in majority of patients with sporadic thoracic aortic aneurysm and dissections (STAAD) remains unknown. Recent GWAS study suggested common variant(s) in FBN1 is associated with STAAD. The present study aims to test this hypothesis and to identify mutation spectrum by targeted exome sequencing of the FBN1 gene in 146 unrelated patients with STAAD. Totally, 15.75% of FBN1 variants in STAAD were identified, including 5 disruptive and 18 missense mutations. Most of the variants were novel. Genotype-phenotype correlation analysis suggested that the maximum aortic diameter in the disruptive mutation group was significantly larger than that in the non-Cys missense mutation group. Interestingly, the variant Ala27Thr at −1 position, which is predicted to change the cleavage site of the signal peptidase of fibrillin-1, was detected in two unrelated patients. Furthermore, genotyping analysis of this variant detected 10 heterozygous Ala27Thr from additional 666 unrelated patients (1.50%), versus 7 from 1500 controls (0.47%), indicating a significant association of this variant with STAAD. Collectively, the identification of the variant Ala27Thr may represent a relatively common genetic predisposition and a novel pathogenetic mechanism for STAAD. Also, expansion of the mutation spectrum in FBN1 will be helpful in genetic counselling for Chinese patients with STAAD.
- 14 August 2015
- Published by Springer Nature in Scientific Reports
- Vol. 5 (1) , 13115
Open AccessWide mutation spectrum and frequent variant Ala27Thr of FBN1 identified in a large cohort of Chinese patients with sporadic TAAD
Genetic etiology in majority of patients with sporadic thoracic aortic aneurysm and dissections (STAAD) remains unknown. Recent GWAS study suggested common variant(s) in FBN1 is associated with STAAD. The present study aims to test this hypothesis and to identify mutation spectrum by targeted exome sequencing of the FBN1 gene in 146 unrelated patients with STAAD. Totally, 15.75% of FBN1 variants in STAAD were identified, including 5 disruptive and 18 missense mutations. Most of the variants were novel. Genotype-phenotype correlation analysis suggested that the maximum aortic diameter in the disruptive mutation group was significantly larger than that in the non-Cys missense mutation group. Interestingly, the variant Ala27Thr at −1 position, which is predicted to change the cleavage site of the signal peptidase of fibrillin-1, was detected in two unrelated patients. Furthermore, genotyping analysis of this variant detected 10 heterozygous Ala27Thr from additional 666 unrelated patients (1.50%), versus 7 from 1500 controls (0.47%), indicating a significant association of this variant with STAAD. Collectively, the identification of the variant Ala27Thr may represent a relatively common genetic predisposition and a novel pathogenetic mechanism for STAAD. Also, expansion of the mutation spectrum in FBN1 will be helpful in genetic counselling for Chinese patients with STAAD.